Nilotinib Viatris (Nilotinib)

Nilotinib targets the BCR‑ABL tyrosine‑kinase pathway, providing therapeutic benefit in specific hematologic malignancies.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves molecular remission in patients with Philadelphia chromosome‑positive disease.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control by inhibiting BCR‑ABL driven signaling.
• Imatinib‑resistant or intolerant CML: offers an alternative oral option when first‑line therapy fails or is not tolerated.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein produced by the Philadelphia chromosome translocation. By binding to the ATP‑binding site of BCR‑ABL, it blocks downstream phosphorylation cascades that drive malignant cell proliferation and survival, leading to apoptosis of leukemic cells while sparing most normal tissues.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often transient.
• Rash: skin erythema or pruritus.
• Headache: mild to moderate intensity.
• Fatigue: generalized tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Pancreatitis: abdominal pain with elevated enzymes.
• Hepatic failure: jaundice, elevated liver enzymes.
• Severe neutropenia: increased infection risk.
• Cardiovascular events: myocardial infarction or stroke.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Patients receiving Nilotinib should be monitored closely for cardiovascular and metabolic effects.

• Cardiac monitoring: assess ECG and QT interval regularly.
• Hematologic monitoring: perform complete blood counts to detect neutropenia or anemia.
• Hepatic monitoring: check liver function tests periodically.
• Drug interaction vigilance: avoid strong CYP3A4 inhibitors and QT‑prolonging agents.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with physician.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nilotinib may interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase nilotinib exposure and toxicity.
• QT‑prolonging drugs (e.g., amiodarone, sotalol): raise risk of cardiac arrhythmias.
• Antacids containing aluminum or magnesium: may reduce nilotinib absorption.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower effectiveness.
• Warfarin: may alter anticoagulation control.
• Statins (e.g., simvastatin): increased risk of myopathy.
• Diuretics: potential electrolyte disturbances affecting QT interval.